Any current/future new fundraising through debt or equity?

Ami Organics has taken Rs. 119 crores of debt to fund the Ankleshwar facility capex. The total capex outlay for the Ankleshwar unit was revised upwards from Rs. 190 crores to Rs. 310 crores, involving additional machinery and infrastructure for a CDMO contract. The company plans to fund capex through a mix of internal accruals and debt; no mention of fresh equity fundraising was made. Finance cost for Q3 was Rs. 25 million and is expected to be similar or slightly higher next quarter due to additional capex borrowings. The overall debt-to-equity ratio after the recent debt is around 63

Any current/future capex/capital investment/strategic investment?

Total capex outlay for Ankleshwar unit revised from Rs. 190 crores to Rs. 310 crores due to additional machinery for CDMO contract and allied infrastructure. Rs. 119 crores debt taken to fund this capex, with overall funding through a mix of internal accruals and debt. Ankleshwar facility upgradation ongoing and expected to complete soon. Rs. 300 crores capex planned, mostly for electrolyte business, but deployment will take some time. Ankleshwar facility expected to have a turnover of 3-3.5x the asset value post-upgrade. No capital infusion planned currently for Baba Fine Chemicals acquisitio

Future growth expectations in sales/revenue/volumes?

Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing erosion. For FY25, revenue growth is expected between 17-22%, driven by ramp-up in Fermion contract, new electrolyte products, and other projects. Volume growth has been strong at 25% year-on-year, indicating robust business traction despite pricing pressures. The company plans to achieve Rs. 1,000 crore revenue target by mid-FY26. Electrolyte additives supply has commenced commercially with long-term contracts signed; capacity expansion planned from 500 MT to 2,000 MT. New Ankleshwar plant

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing pressures. FY25 revenue growth is expected between 17-22%, aided by ramp-up in Fermion contract and new electrolyte projects. EBITDA margin in Q3 FY24 was 15.9%, with a target to increase to 18-20% in the next quarter, and ultimately return towards 23% margin level. Higher margins are expected due to stabilization of raw material prices and improved product mix. EPS and PAT margins were impacted this quarter by lower EBITDA margin, higher depreciation, and finance costs. CAPEX investments (Rs. 300 cr

Current/ Expected Orderbook/ Pending Orders?

Ami Organics has firm orders in hand and has already moved into production, indicating a healthy current order book (Page 11). The company is actively negotiating and in discussions with other pharmaceutical customers for additional contracts, including a 66% capacity facility (Page 15). The Ankleshwar plant has contracts including a significant agreement with Fermion for advanced pharmaceutical intermediates, expected to ramp up gradually through FY25 (Page 15, 20). A Rs. 300 crore toll manufacturing opportunity is targeted to be finalized and operational in FY25 (Page 15). The management exp

IN US

Acutaas Chemicals LtdQ4 FY24Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,261P/E: 69.6Market Cap: ₹26.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing erosion.
→For FY25, revenue growth is expected between 17-22%, driven by ramp-up in Fermion contract, new electrolyte products, and other projects.
→Volume growth has been strong at 25% year-on-year, indicating robust business traction despite pricing pressures.
→The company plans to achieve Rs. 1,000 crore revenue target by mid-FY26.
→Electrolyte additives supply has commenced commercially with long-term contracts signed; capacity expansion planned from 500 MT to 2,000 MT.
→New Ankleshwar plant inauguration and partnerships (e.g., with Fermion) expected to boost higher-value advanced intermediates production.
→Expansion in Specialty Chemical and Pharma Intermediate segments with product ramp-ups expected from Q1 FY25.
→Rs. 300 crore CAPEX underway (e.g., for electrolyte and Ankleshwar facility upgrades) to enable future growth.

Margin guidance

Category 1

→Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing pressures.
→FY25 revenue growth is expected between 17-22%, aided by ramp-up in Fermion contract and new electrolyte projects.
→EBITDA margin in Q3 FY24 was 15.9%, with a target to increase to 18-20% in the next quarter, and ultimately return towards 23% margin level.
→Higher margins are expected due to stabilization of raw material prices and improved product mix.
→EPS and PAT margins were impacted this quarter by lower EBITDA margin, higher depreciation, and finance costs.
→CAPEX investments (Rs. 300 crores) in Ankleshwar facility and electrolyte business expected to drive long-term growth.
→Volume growth remains strong at 25% YoY, supporting revenue and margin expansion over the medium term.
→Management remains confident about maintaining quality growth and margin recovery in upcoming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Ami Organics has taken Rs. 119 crores of debt to fund the Ankleshwar facility capex.
→The total capex outlay for the Ankleshwar unit was revised upwards from Rs. 190 crores to Rs. 310 crores, involving additional machinery and infrastructure for a CDMO contract.
→The company plans to fund capex through a mix of internal accruals and debt; no mention of fresh equity fundraising was made.
→Finance cost for Q3 was Rs. 25 million and is expected to be similar or slightly higher next quarter due to additional capex borrowings.
→The overall debt-to-equity ratio after the recent debt is around 63% debt and 37% equity, indicating no immediate plans for equity dilution.
→No explicit future plans for new fundraising (debt or equity) beyond these were discussed in the call.

Order book

→Ami Organics has firm orders in hand and has already moved into production, indicating a healthy current order book (Page 11).
→The company is actively negotiating and in discussions with other pharmaceutical customers for additional contracts, including a 66% capacity facility (Page 15).
→The Ankleshwar plant has contracts including a significant agreement with Fermion for advanced pharmaceutical intermediates, expected to ramp up gradually through FY25 (Page 15, 20).
→A Rs. 300 crore toll manufacturing opportunity is targeted to be finalized and operational in FY25 (Page 15).
→The management expects revenue growth and capacity utilization to improve as these orders ramp up, aiming for Rs. 1,000 crore revenue by mid-FY26 (Page 20).

Capex plans

Yes

→Total capex outlay for Ankleshwar unit revised from Rs. 190 crores to Rs. 310 crores due to additional machinery for CDMO contract and allied infrastructure.
→Rs. 119 crores debt taken to fund this capex, with overall funding through a mix of internal accruals and debt.
→Ankleshwar facility upgradation ongoing and expected to complete soon.
→Rs. 300 crores capex planned, mostly for electrolyte business, but deployment will take some time.
→Ankleshwar facility expected to have a turnover of 3-3.5x the asset value post-upgrade.
→No capital infusion planned currently for Baba Fine Chemicals acquisition; it is an established business.
→Capacity expansion planned for electrolyte additives: from current 500 metric tons each to an additional 2,000 metric tons each.
→Electrolyte CDMO business is CAPEX intensive with standard multi-year ramp-up timeline.

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Acutaas Chemicals Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Acutaas Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio